Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
The Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) news page on Stock Titan aggregates company announcements, scientific conference updates and regulatory disclosures related to its Actinium-225 targeted radiotherapy programs. Actinium regularly issues press releases detailing preclinical and clinical data, corporate events and participation in oncology meetings, offering investors and observers insight into the evolution of its pipeline.
Recent news has focused heavily on ATNM-400, the company’s first-in-class, multi-indication Ac-225 antibody radioconjugate. Actinium has reported preclinical data for ATNM-400 in metastatic castration-resistant prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer, including models resistant to standard-of-care therapies such as enzalutamide, 177Lu-PSMA-617, osimertinib, tamoxifen and trastuzumab. Releases describe superior tumor growth inhibition versus several approved agents, durable tumor control, and synergistic effects when ATNM-400 is combined with ARPIs or EGFR inhibitors.
News items also cover Actimab-A, a CD33-targeting Ac-225 therapeutic for acute myeloid leukemia, including its planned pivotal Phase 2/3 trial and a Cooperative Research and Development Agreement with the National Cancer Institute. Additional updates describe Iomab-ACT and Iomab-B in conditioning for bone marrow transplant and cell or gene therapies, as well as Actinium’s broader research efforts in solid tumors.
Visitors to this page can review earnings‑independent scientific updates, conference abstracts and corporate communications that outline Actinium’s development strategy, preclinical results and governance milestones such as annual meeting outcomes. For anyone tracking ATNM as an oncology development story, this news feed provides a centralized view of how the company portrays progress across its Ac‑225 radiotherapy platform.
Actinium Pharmaceuticals (NYSE: ATNM) announced Mark Kubik's appointment as Chief Business Officer, effective immediately. Kubik, formerly with OncoImmune, will lead business development, focusing on partnerships and advancing Actinium's AWE technology and pipeline of antibody radiation conjugates (ARCs). His extensive background includes a successful acquisition of OncoImmune by Merck for $425 million. Actinium expects significant developments in 2021, including completing SIERRA enrollment and proof of concept data across multiple clinical programs, enhancing its research capabilities and portfolio.
Actinium Pharmaceuticals (NYSE: ATNM) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company's executive team will hold one-on-one meetings with attendees. Actinium is focused on developing ARCs—Antibody Radiation-Conjugates for targeted conditioning in cancer treatments, particularly for Bone Marrow Transplants. Their lead candidate, I-131 apamistamab (Iomab-B), is in a pivotal Phase 3 trial for elderly patients with relapsed or refractory acute myeloid leukemia. The trial is over 75% enrolled, with positive early data reported at major conferences.
Actinium Pharmaceuticals (ATNM) showcased its pivotal Phase 3 SIERRA trial for Iomab-B at the 2021 TCT Annual Meeting, highlighting significant progress in targeted conditioning for bone marrow transplants. Key findings include a 100% BMT rate for Iomab-B patients versus 18% for conventional therapy. Additionally, 79% of patients in the SIERRA trial proceeded to BMT, indicating strong efficacy. The company's focus on advancing Iomab-ACT and future milestones suggests a positive outlook for 2021, with expectations of completing enrollment and presenting further trial results.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the BIO CEO & Investor conference from February 16-18, 2021. Actinium's executive team will hold one-on-one meetings with attendees through the BIO One-on-One Partnering™ system. The company focuses on developing Antibody Radiation-Conjugates (ARCs) for treating cancers, including its lead product, I-131 apamistamab (Iomab-B), which is in a pivotal Phase 3 trial for elderly patients with relapsed or refractory acute myeloid leukemia. This trial is over 75% enrolled and has positive preliminary data from prior meetings.
Actinium Pharmaceuticals (NYSE: ATNM) announced its participation in the B. Riley Oncology Investor Conference, scheduled virtually from January 20-21, 2021. Key executives, including Sandesh Seth (Chairman and CEO), Dr. Mark Berger (Chief Medical Officer), and Dr. Dale Ludwig (Chief Scientific Officer), will engage in a moderated discussion led by analyst Justin Walsh. The chat is set for January 21 at 3:30 p.m. ET. Additionally, the executive team is open for one-on-one meetings with attendees.
Actinium Pharmaceuticals (NYSE: ATNM) announced a research collaboration with Astellas Pharma to develop targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology. This partnership aims to utilize Actinium-225 in combination with selected targeting agents from Astellas, contributing to the latter's Rx+ ® initiative for theranostics. Actinium’s AWE platform, protected by a robust intellectual property portfolio, positions the company favorably for this collaboration. Actinium plans to leverage its clinical experience and laboratory capabilities to enhance targeted therapies.
Actinium Pharmaceuticals (ATNM) announced positive interim results from the pivotal Phase 3 SIERRA study for Iomab-B, designed for bone marrow transplant conditioning in older patients with relapsed or refractory AML. The independent Data Monitoring Committee recommended the trial continue, as 100% of patients receiving Iomab-B proceeded to transplant versus 16% in the control arm. Safety data presented at the ASH 2020 Annual Meeting indicated lower rates of serious adverse events in the Iomab-B group. The trial aims to complete enrollment of 150 patients, with over 75% already enrolled.
Actinium Pharmaceuticals (NYSE: ATNM) participated in the virtual Targeted Radiopharmaceuticals Summit from December 8-10, 2020. CEO Sandesh Seth highlighted the company's leadership in targeted radiotherapy and provided updates on its promising clinical programs for Acute Myeloid Leukemia (AML), particularly Iomab-B and Actimab-A. The company aims to leverage its proprietary AWE technology platform for novel targeted therapies. Notably, the pivotal Phase 3 SIERRA trial for Iomab-B is over 75% enrolled, with significant safety data previously presented at major oncology meetings.
Actinium Pharmaceuticals (NYSE: ATNM) announced promising results for its Actimab-A and venetoclax combination therapy in a Phase 1 trial for relapsed or refractory Acute Myeloid Leukemia (AML). Presented at the ASH annual meeting, data indicated one patient achieved a complete remission after the first cycle, with no significant toxicity reported. The trial has progressed to the second dose cohort, reinforcing Actinium's clinical development strategy aimed at enhancing therapeutic efficacy while minimizing side effects.
Actinium Pharmaceuticals (NYSE: ATNM) presented interim data from its pivotal Phase 3 SIERRA trial in relapsed or refractory Acute Myeloid Leukemia at the ASH annual meeting. With 75% patient enrollment, 100% of 49 patients receiving Iomab-B proceeded to Bone Marrow Transplant (BMT), compared to 16% in the control arm. Among those who crossed over from the control group, 100% also proceeded to BMT. The trial shows a durable Complete Remission potential of 77% in the Iomab-B arm versus 12% in the control, highlighting Iomab-B's effectiveness in older, at-risk patients.
FAQ
What is the current stock price of Actinium Pharmac (ATNM)?
What is the market cap of Actinium Pharmac (ATNM)?
